Use of single-pill combination therapy in the evolving paradigm of hypertension management
- PMID: 19496740
- DOI: 10.1517/14656560902980210
Use of single-pill combination therapy in the evolving paradigm of hypertension management
Abstract
The use of antihypertensive therapy is an evolving paradigm. Although blood pressure (BP) control rates remain low, there have been improvements that may be attributable in part to a recent shift in clinical guidelines that recognizes that most patients will require multiple drugs to reach BP goals and encourages clinicians to use combination therapy as first-line treatment in selected patients. Single-pill combinations of two complementary antihypertensive medications offer benefits beyond those of separate administration of the individual component agents, providing a simpler medication regimen that is effective and well tolerated while enhancing patient adherence to therapy. In the future, there may be single-pill combinations of three antihypertensive drugs to further enhance BP control rates.
Similar articles
-
Improving blood pressure control rates by optimizing combination antihypertensive therapy.Expert Opin Pharmacother. 2010 Aug;11(12):2011-26. doi: 10.1517/14656566.2010.500614. Expert Opin Pharmacother. 2010. PMID: 20590485 Review.
-
Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.J Cardiovasc Nurs. 2009 Sep-Oct;24(5):380-9. doi: 10.1097/JCN.0b013e3181aed18e. J Cardiovasc Nurs. 2009. PMID: 19707098 Review.
-
Issues in blood pressure control and the potential role of single-pill combination therapies.Int J Clin Pract. 2009 May;63(5):790-8. doi: 10.1111/j.1742-1241.2009.01999.x. Epub 2009 Feb 11. Int J Clin Pract. 2009. PMID: 19220523 Review.
-
Single-pill combination of amlodipine and valsartan in the management of hypertension.Expert Opin Pharmacother. 2009 Aug;10(12):1979-94. doi: 10.1517/14656560903120899. Expert Opin Pharmacother. 2009. PMID: 19606937 Review.
-
A role for single-pill triple therapy in hypertension.Ther Adv Cardiovasc Dis. 2009 Jun;3(3):231-40. doi: 10.1177/1753944709334947. Epub 2009 May 14. Ther Adv Cardiovasc Dis. 2009. PMID: 19443512 Review.
Cited by
-
Long-term efficacy and safety of triple-combination therapy with olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide for hypertension.J Clin Hypertens (Greenwich). 2012 Mar;14(3):149-57. doi: 10.1111/j.1751-7176.2011.00588.x. Epub 2012 Jan 24. J Clin Hypertens (Greenwich). 2012. PMID: 22372774 Free PMC article. Clinical Trial.
-
Combined olmesartan, amlodipine, and hydrochlorothiazide therapy in randomized patients with hypertension: a subgroup analysis of the TRINITY study by age.Drugs Aging. 2013 Jul;30(7):549-60. doi: 10.1007/s40266-013-0072-1. Drugs Aging. 2013. PMID: 23549909 Free PMC article. Clinical Trial.
-
Role of olmesartan in combination therapy in blood pressure control and vascular function.Vasc Health Risk Manag. 2010 Sep 7;6:701-9. doi: 10.2147/vhrm.s6663. Vasc Health Risk Manag. 2010. PMID: 20859541 Free PMC article. Review.
-
Olmesartan/amlodipine/hydrochlorothiazide in participants with hypertension and diabetes, chronic kidney disease, or chronic cardiovascular disease: a subanalysis of the multicenter, randomized, double-blind, parallel-group TRINITY study.Cardiovasc Diabetol. 2012 Oct 30;11:134. doi: 10.1186/1475-2840-11-134. Cardiovasc Diabetol. 2012. PMID: 23110471 Free PMC article. Clinical Trial.
-
Small-Molecule Dual PLK1 and BRD4 Inhibitors are Active Against Preclinical Models of Pediatric Solid Tumors.Transl Oncol. 2020 Feb;13(2):221-232. doi: 10.1016/j.tranon.2019.09.013. Epub 2019 Dec 21. Transl Oncol. 2020. PMID: 31869746 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical